Compare TZOO & AIDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TZOO | AIDX |
|---|---|---|
| Founded | 1998 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Precision Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 60.3M | 58.8M |
| IPO Year | 2003 | N/A |
| Metric | TZOO | AIDX |
|---|---|---|
| Price | $5.62 | $1.74 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.00 | N/A |
| AVG Volume (30 Days) | 145.6K | ★ 206.5K |
| Earning Date | 04-28-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.41 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $10.57 | N/A |
| Revenue Next Year | $9.35 | N/A |
| P/E Ratio | $13.90 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.72 | $1.51 |
| 52 Week High | $16.56 | $14.09 |
| Indicator | TZOO | AIDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.94 | 10.56 |
| Support Level | $4.72 | $1.60 |
| Resistance Level | $6.07 | $1.87 |
| Average True Range (ATR) | 0.33 | 0.28 |
| MACD | -0.09 | 0.22 |
| Stochastic Oscillator | 18.80 | 17.71 |
Travelzoo acts as a publisher of travel and entertainment offers. It operates in four segments. Travelzoo North America segment, which is the key revenue driver, consists of operations in Canada and the U.S.; Travelzoo Europe segment consists of operations in France, Germany, Spain, and the U.K.; Jack's Flight Club segment consists of subscription revenue from premium members to access and receive flight deals from Jack's Flight Club via email or via Android or Apple mobile applications; and New Initiatives consists of Travelzoo's licensing activities in Asia Pacific territories. It derives its revenue through advertising fees including listing fees paid by travel, entertainment, and local businesses to advertise their offers on the company's media properties.
20/20 Biolabs Inc is a commercial stage diagnostics company with the core mission of developing and commercializing clinical laboratory tests for early disease detection and prevention and associated software that is powered by machine learning and real-world data to improve diagnostic accuracy and clinical utility. The company offers two OneTest lab products; OneTest for Cancer that inludes primary MCED blood test and revenue source post-COVID and OneTest for Longevity that consists of inflammatory biomarkers.